Bioventus Inc.
BVS
Rank in Stocks
#10030
Bioventus Inc., a medical device company, focuses on relieving pain and... Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Share Price
$11.02
Last synced: 2026-11-09
Market Cap
$754.24M
Change (1 day)
3.82%
Change (1 year)
43.05%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Bioventus Inc. (BVS)
Category
Healthcare
Operating Margin for Bioventus Inc. (BVS)
Operating Margin as of November 2026 TTM: 10.63%
According to Bioventus Inc.'s latest financial reports, its current operating margin (TTM) is 10.63%. At the end of 2025 the company had an operating margin of 10.31%.
Operating Margin history for Bioventus Inc. from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 10.63% | 3.10% |
| 2025 | 10.31% | -593.30% |
| 2024 | -2.09% | -86.90% |
| 2023 | -15.95% | -51.16% |
| 2022 | -32.66% | -1,266.43% |
| 2021 | 2.80% | -57.64% |
| 2020 | 6.61% | -27.92% |
| 2019 | 9.17% | 14.77% |
| 2018 | 7.99% | -13.62% |
| 2017 | 9.25% | 70.66% |
| 2016 | 5.42% | -182.87% |
| 2015 | -6.54% | -65,500.00% |
| 2014 | 0.01% | -100.29% |
| 2013 | -3.47% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 15.24% | -98.57% |
US
|
|
| 18.08% | -98.30% |
IE
|
|
| 21.25% | -98.00% |
US
|
|
| 21.05% | -98.02% |
US
|
|
| 28.09% | -97.36% |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Bioventus Inc.'s operating margin
What is Bioventus Inc.'s operating margin?
Bioventus Inc.'s operating margin is 10.63%, as of Nov 2026.
What was Bioventus Inc.'s operating margin in 2025?
In 2025, Bioventus Inc.'s operating margin was 10.31%, compared with -2.09% in 2024.
How has Bioventus Inc.'s operating margin changed since 2020?
From 2020 to 2025, Bioventus Inc.'s operating margin was highest in 2025 (10.31%) and lowest in 2022 (-32.66%).
How does Bioventus Inc.'s operating margin compare with similar companies?
Bioventus Inc.'s operating margin (10.63%) is lower than that of all 5 similar companies listed above. The highest among them is Edwards Lifesciences Corporation, with 28.09%.